Search results
Results from the WOW.Com Content Network
Overactive bladder (OAB) is a common condition where there is a frequent feeling of needing to urinate to a degree that it negatively affects a person's life. [2] The frequent need to urinate may occur during the day, at night , or both. [ 4 ]
Print/export Download as PDF; Printable version; In other projects Wikidata item; Appearance. move to sidebar hide. OAB may stand for: Order of Attorneys of Brazil ...
A Phase II study of solabegron for overactive bladder (OAB) looked at 258 patients with moderate-to-severe incontinence experiencing an average of 4.5 wet episodes per day. Results demonstrated a statistically significant improvement with solabegron as compared with placebo, as measured by the percentage reduction of the number of wet episodes ...
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
Oxybutynin, sold under the brand name Ditropan among others, is an anticholinergic medication primarily used to treat overactive bladder.It is widely considered a first-line therapy for overactive bladder due to its well-studied side effect profile, broad applicability, and continued efficacy over long periods of time.
More than 1 million Americans live with human immunodeficiency virus, or HIV, with tens of thousands of new diagnoses each year. But with earlier diagnoses and advances in treatment, HIV, the ...
Fesoterodine (INN, used as the fumarate under the brand name Toviaz) is an antimuscarinic drug developed by Schwarz Pharma AG to treat overactive bladder syndrome (OAB). [2] It was approved by the European Medicines Agency in April 2007, [3] the US Food and Drug Administration on October 31, 2008 [4] and Health Canada on February 9, 2012.
Page 2 of 45 Association, Hispanic Lawyers’ Association of Illinois, Illinois State Bar Association, Lesbian and Gay Bar Association of Chicago, Puerto Rican Bar Association, and the Women’s Bar Association of Illinois.